Vildagliptin is a DPP-4 (iDPP-4) inhibitor drug. Among its drug reactions, the dermatological manifestation of bullous pemphigoid (BP), a chronic, rare, autoimmune and subepidermal disease, has been described. We present the case of a patient with antecedent diabetes type 2, who was under treatment with metformin, empaglifozin and vildagliptin; he presented vesicular papular lesions with erythematous bases, visualized on arms, legs and trunk. Hypoglycemic treatment was suspended, immunosuppressive therapy was started and after immunosuppressive management, dermatological lesions improved. This case report is a scientific documentation base on BP in patients with vildagliptin.